


# Rate of CVD mortality, MI, stroke down for patients on semaglutide

September 17 2016

---



(HealthDay)—Semaglutide is noninferior to placebo for patients with

type 2 diabetes at high cardiovascular risk, according to a study published online Sept. 16 in the *New England Journal of Medicine*. The research was published to coincide with the annual meeting of the European Association for the Study of Diabetes, held from Sept. 12 to 16 in Munich.

Steven P. Marso, M.D., from Research Medical Center in Kansas City, Mo., and colleagues randomized 3,297 patients with type 2 diabetes to receive once-weekly semaglutide or placebo for 104 weeks. At baseline, 83.0 percent of the patients had established [cardiovascular disease](#), [chronic kidney disease](#), or both.

The researchers found that the primary outcome (composite of first occurrence of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) occurred in 6.6 percent of patients in the semaglutide group and in 8.9 percent of the [placebo group](#) (hazard ratio, 0.74; 95 percent confidence interval, 0.58 to 0.95; P

"The rate of [cardiovascular death](#), nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide," the authors write.

Several authors disclosed financial ties to Novo Nordisk, which manufactures semaglutide and funded the study.

**More information:** [Abstract](#)  
[Full Text](#)  
[More Information](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Rate of CVD mortality, MI, stroke down for patients on semaglutide (2016, September 17) retrieved 26 April 2024 from <https://medicalxpress.com/news/2016-09-cvd-mortality-mi-patients-semaglutide.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.